Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 312 matching trials from the live ClinicalTrials.gov search.

Filters: "biochemical recurrence" Condition: Prostate Cancer Clear all

Conditions: Prostate Cancer
Interventions: GnRH agonist, Anti-androgen, TAK-700, Radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 165
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more

Conditions: Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer
Interventions: Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Angela Y. Jia, MD PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix; Procedure · Drug · Other + 1 more
Lead sponsor: Sean Sachdev; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer
Interventions: MBM-02; Drug
Lead sponsor: Matrix Biomed, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Marina del Rey, California

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
Interventions: Stereotactic Body Radiation Therapy with Integrated Boost; Radiation
Lead sponsor: John Fiveash, MD; Other
Eligibility: 19 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 594
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review; Procedure · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Adenocarcinoma of the Prostate
Interventions: enzalutamide; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostatic Neoplasms, Pelvic Nodal
Interventions: Enzalutamide, Leuprolide, Intensity-Modulated Radiation Therapy; Drug · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostatic Neoplasms
Interventions: Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Adenocarcinoma
Interventions: Lu-17-PSMA-617; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Prostate Cancer
Interventions: flutamide, Zoladex, Lupron, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 222
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Adenocarcinoma, Prostate Cancer
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy; Drug · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: bicalutamide, radiation therapy, placebo; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Male only
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2022
U.S. locations: 221
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more

Conditions: Prostate Cancer
Interventions: Radiation therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25); Radiation · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Cancer of Prostate
Interventions: ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Cryotherapy
Interventions: 64Cu-SAR-bisPSMA; Drug
Lead sponsor: Clarity Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • Montebello, California + 15 more

Conditions: Prostate Cancer
Interventions: Ad5-yCD/mutTKSR39rep-hIL12; Biological
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer Adenocarcinoma
Interventions: 30Gy (Gray) planning target volume (PTV); Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Colorado Springs, Colorado + 5 more

Conditions: Prostate Cancer
Interventions: 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Ga-68 labeled PSMA-11 PET; Drug
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Enzalutamide in Patients With High-risk Prostate Cancer

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

SBRT for Organ Confined Prostate Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Tecemotide (L-BLP25) in Prostate Cancer

De-implementation of Low Value Castration for Men With Prostate Cancer

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer

Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence